Ibrahim Tora, MD
Pulmonary Disease · Portsmouth, OHNPI 1699269076
Payments from drug & device makers
What this record shows
This record is dominated by travel and lodging: $1,027 of the $1,692 with a category attached, or 60.7%. Pulmonx Corporation accounts for 70.5% of it on its own, with 12 other manufacturers making up the rest. That places this record below the midpoint for pulmonary disease clinicians in OH, where the typical reported total is $1,293.
Across 27 payments — averaging $62.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pulmonx Corporation$1K
- Sanofi$116
- United Therapeutics Corporation$70
- AstraZeneca$59
- Regeneron Healthcare Solutions, Inc.$58
- Takeda Pharmaceuticals U.S.A., Inc.$44
- plus $151 from 7 others
What the payments were for
- Travel & lodging$1,02761%
- Food & beverage$66539%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pulmonx Corporation | 4 | $1,193 |
| Sanofi | 4 | $116 |
| United Therapeutics Corporation | 3 | $70 |
| AstraZeneca | 4 | $59 |
| Regeneron Healthcare Solutions, Inc. | 2 | $58 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $44 |
| Philips North America LLC | 2 | $35 |
| Inogen, Inc. | 1 | $21 |
| Genentech USA, Inc. | 1 | $21 |
| ANI Pharmaceuticals, Inc. | 1 | $20 |
| GSK | 1 | $20 |
| Boston Scientific | 1 | $19 |
| Merck | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,692 in reported general payments places this provider in the 50th percentile of 571 pulmonary disease providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other pulmonary disease in Portsmouth
- Joseph KhabbazaAkron$655K
- Robert BaughmanCincinnati$640K
- Kristin HighlandCleveland$551K
- Bruce CorserCincinnati$502K
- Jason StieneckerLima$397K
- Mohammad SheattCincinnati$389K
- Mohammad KhanAkron$388K
- Thomas YungerDayton$353K
- Joseph CiceniaCleveland$350K
- Jean ElwingCincinnati$320K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.